BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25875256)

  • 1. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
    Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
    Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
    De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
    Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
    Özdede A; Hatemi G
    Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
    Deeks ED
    Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
    Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
    Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast to treat oral ulcers in Behçet syndrome.
    Yazici H
    Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positioning of apremilast in treatment of Behçet's disease.
    Takeno M
    Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
    Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
    Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
    Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
    Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
    Front Immunol; 2020; 11():626792. PubMed ID: 33613571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.
    Genovese MC; Jarosova K; Cieślak D; Alper J; Kivitz A; Hough DR; Maes P; Pineda L; Chen M; Zaidi F
    Arthritis Rheumatol; 2015 Jul; 67(7):1703-10. PubMed ID: 25779750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.